Although the introduction of novel targeted agents has improved patient outcomes in several human cancers, no such advance has been achieved in muscle-invasive bladder cancer (MIBC). However, recent sequencing efforts have begun to dissect the complex genomic landscape of MIBC, revealing distinct molecular subtypes and offering hope for implementation of targeted therapies. Her2 (ERBB2) is one of the most established therapeutic targets in breast and gastric cancer but agents targeting Her2 have not yet demonstrated anti-tumor activity in MIBC. Through an integrated analysis of 127 patients from three centers, we identified alterations of Her2 at the DNA, RNA and protein level, and demonstrate that Her2 relevance as a tumor driver likely may vary even within ERBB2 amplified cases. Importantly, tumors with a luminal molecular subtype have a significantly higher rate of Her2 alterations than those of the basal subtype, suggesting that Her2 activity is also associated with subtype status. Although some of our findings present rare events in bladder cancer, our study suggests that comprehensively assessing Her2 status in the context of tumor molecular subtype may help select MIBC patients most likely to respond to Her2 targeted therapy.
Muscle invasive bladder cancer (MIBC) is a highly aggressive disease, with a 5 year survival rate post-diagnosis of approximately 50%1,2. Although the implementation of neoadjuvant chemotherapy extended overall patient survival3,4, prior to the recent advent of immune checkpoint inhibitors, no relevant new therapies have been introduced in the last 3 decades5,6. This is in stark contrast to several other major cancers7,8,9,10,11,12.
Her2 (gene name: ERBB2) is a member of the epidermal growth factor receptor (EGFR) family, and one of the best-known therapeutic targets in oncology. Her2 can activate intracellular pathways that promote proliferation, survival, mobility and invasiveness of tumor cells and these aggressive oncogenic features translate into reduced survival in patients with Her2-overexpressing breast and gastric cancers11,13. In these cancers, gene amplification is the primary mechanism for Her2 overexpression and Her2 targeted therapies (e.g. trastuzumab or lapatinib) have become a standard treatment in appropriate tumors7,11. MIBC has the third highest rate of ERBB2 amplification (after breast and gastric cancer)14 and demonstrates frequent Her2 overexpression15,16. Even so, anti-Her2 treatments in MIBC have not been as encouraging17,18,19,20 and despite best practice patient selection by fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC), question whether bladder cancer can respond to Her2 targeted therapy. However, these instruments for patient selection have been developed and shown to be successful in patients with breast or gastric cancers and might not be optimal in those with MIBC.
The identification of tumor molecular subtypes by four separate research groups is one of the most important recent discoveries in MIBC14,21,22,23. On a higher level, all represent a division into basal and luminal tumors. Within this framework, each system made specific subclassifications. For example, through RNA profiling of hundreds of MIBC tumors, The Cancer Genome Atlas (TCGA) Research Network identified four distinct clusters that are each associated with specific biological characteristics, pathway activities, and clinical behavior/outcomes14. Clusters I and II have predominantly luminal characteristics, express markers of urothelial differentiation such as uroplakins, express the same cytokeratins as the luminal layer of the normal urothelium (KRT18 and KRT20) and exhibit a strong peroxisome proliferator activator receptor (PPAR) pathway activation. Cluster III and IV represent basal tumors, identified by squamous features, expression of cytokeratins (KRT14 and KRT5) and a higher proliferation rate than luminal tumors. These resemble the basal/stem cell compartment of the normal urothelium. In addition, cluster IV tumors show the highest immune infiltration. As a consequence, contemporary biomarker studies must account for the possibility that the baseline characteristics, biological role and significance of genomic alterations may vary between molecular subtypes.
We hypothesized that an integrated approach to Her2 characterization in MIBC may better guide patient prioritization for targeted therapy. Therefore, we assembled a cohort of MIBC patients from three academic centers, identified Her2 alterations at the DNA, RNA and protein level and dissected the relationship of alterations to each other and in the context of the TCGA clusters. We demonstrate that it is necessary to analyze Her2 on all three levels to sufficiently characterize all alterations, and suggest that such comprehensive analysis will provide optimal patient stratification for future Her2-targeted trials.
Material and Methods
We selected a retrospective consecutive cohort of 127 patients from three tertiary centers (Supp Table 1). All patients were diagnosed with muscle-invasive urothelial bladder cancer and clinical staging included computed tomography (CT) scan of the abdomen and pelvis, chest x-ray (or chest CT) and bone scan. All patients received at least 3 cycles of neoadjuvant chemotherapy (NAC) with gemcitabine and cisplatin prior to cystectomy and pelvic lymph node dissection. Patients receiving other chemotherapy regimens or not undergoing cystectomy were excluded. Follow-up varied according to centre, but usually included evaluation at 3 and 6 months postoperatively, every 6-months up to 5 years and yearly thereafter.
Pre-chemotherapy bladder tumor specimens from transurethral resection (TURBT) were used for analysis. All tissue slides from each patient were re-evaluated for this study by two investigators blinded to patient outcome. One haematoxylin and eosin stained section was taken per tissue block and tumor grade was assessed microscopically. In combination with clinical parameters, all tumors were staged according to the seventh International Union Against Cancer (UICC) classification of 200924. A tissue microarray (TMA)25 was constructed with two cores per patient from the invasive tumor component.
Fluorescence in-situ hybridization (FISH) and Immunohistochemistry (IHC)
Two sections of 3 μm thickness were taken and the FISH reactions were performed according to the FISH Her2 PharmDx (DAKO) protocol. The kit contains a mixture of Texas Red-labeled DNA cosmid clones of the Her2 amplicon and a mixture of fluorescein labeled peptide nucleic acid probes targeting the centromeric region of chromosome 17. The slides were processed according to the manufacturer’s protocol: after deparaffination, sections were immersed in pretreatment solution at 95 °C for 20 minutes followed by pepsin enzymatic digestion (15 minutes) at room temperature. Her2/CEN-17 probe was applied and denatured at 82 °C for 5 minutes. Hybridization was performed overnight at 45 °C. Stringent washes were performed followed by 4,6-diamidino-2-phenylindole staining. Thirty tumor nuclei were evaluated per tissue spot and assigned as negative, equivocal or amplified (Fig. 1A and B and Supp Figure 1A and B) according to the recommendations of the American Society of Clinical Oncology/College of American Pathologists26 (Her2/CEP17 ratio <2.0 and Her2 copy number <4.0: negative, ratio <2.0 and Her2 copy number ≥4.0 and <6.0: equivocal, ratio ≥2.0 or copy number ≥6.0: amplified).
The original Hercep Test™ was used for immunohistochemical Her2 protein detection. Her2 expression per tissue spot was classified according to the modified DAKO criteria: negative (0/1+), equivocal (2+) and positive (3+) (Fig. 1C and D and Supp Figure 1C and D) with a cut-off for score 3+ of more than 10% strongly positive cells26.
All FISH and IHC staining were performed at the Institute of Pathology, University of Bern, Switzerland. This laboratory is certified, has extensive Her2 IHC and FISH expertise and takes part in external proficiency testing.
Total RNA was extracted from a 1 mm diameter core punch of the tumor with the RNeasy FFPE kit (Qiagen, Valencia, CA), followed by amplification and labeling with the Ovation WTA FFPE system and Encore Biotin Module (both NuGen, San Carlos, CA), respectively. cDNA hybridization to GeneChip Human Exon 1.0 ST oligonucleotide microarrays (Affymetrix, Santa Clara, CA) was performed according to the manufacturer’s recommendations. The Affymetrix Power Tools package was used for quality control27 and mRNA expression data was normalized using SCAN28. This analysis was performed by GenomeDx Biosciences, a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Array files are available from the National Center for Biotechnology Information’s Gene Expression Omnibus (NCBI–GEO) database (http://www.ncbi.nlm.nih.gov/geo/) under GEO accession code GSE87304.
DNA was extracted from TURBT specimens from the same cohort; tissue of 96 specimens was available for DNA extraction. Extracted DNA (100 ng) was sheared to 100–400 bp by sonication and was subjected to end-repair, dA-addition, and ligation of indexed IonProton sequencing adaptors. Libraries were hybridization-captured using a pool of >24 000 individually synthesized 50-biotinylated DNA oligonucleotides. In total, 83/96 TURBT specimens passed all QC metrics and had available data on exome DNA sequencing. Synonymous single nucleotide variants (SNV), as well as variants falling in UTRs and introns of ERBB2 were not considered. Non-synonymous (missense) SNVs were called when reported in COSMIC database or with a variant read ≥10 and an allele frequency of ≥10%. All SNVs were validated visually. To determine Copy Number variations (CNV), data analysis was performed using Nexus Copy Number Software, Version 8.0 (BioDiscovery, Hawthorne, CA). Samples were processed using the Nexus NGS functionality (BAM ngCGH) with the FASST2 Segmentation algorithm to make copy number calls (a Circular Binary Segmentation/Hidden Markov Model approach). The significance threshold for segmentation was set at 5 × 10−6, also requiring a minimum of 3 probes per segment and a maximum probe spacing of 1000 between adjacent probes before breaking a segment. The logratio thresholds for single copy gain and single copy loss were set at +0.2 and −0.02, respectively. The logratio thresholds for gain of 2 or more copies and for a homozygous loss were set at +0.6 and −1.0, respectively. Tumor sample BAM files were processed with corresponding normal tissue BAM files. Reference reads per CN point (window size) was set at 8000. Probes were normalized to median. The genomic sequencing was performed at laboratory for advanced genomic analysis of the Vancouver Prostate Centre that uses validated and approved experimental protocols.
The number of samples available for each analysis is given in Supp Table 1.
The TCGA bladder cohort
The TCGA Bladder Urothelial Carcinoma dataset (n = 407) was downloaded from the Broad Institute Firehose Pipeline (http://gdac.broadinstitute.org) on May, 10, 2016. Genomic DNA sequencing with ERBB2 mutation calls (n = 407), CNV (n = 403), gene expression (n = 407), methylation analysis (HM450, n = 407) and reverse phase protein assay (RPPA) data for protein expression (n = 339) were used. For analysis of clinical outcomes only patients without neoadjuvant chemotherapy were selected (n = 397). As above, SNVs that did not alter the amino acid code of ERBB2 were not considered. Missense SNVs were called when reported in COSMIC database or with a variant read ≥10 and an allele frequency of ≥10%.
In both cohorts (our NAC cohort and TCGA), gene expression data was used to assign tumors to the TCGA clusters. The original “Classification to Nearest Centroids” (ClaNC) model was used14.
Statistical analysis was conducted using R Software Package, version 3.1.0. For comparison of non-categorical data between two and more groups logistic regression (lr) was used, respectively. Categorical data were compared using exact Fisher’s test. Pearson correlation was performed to compare the correlation between continuous parameters. Kaplan-Meier plots estimated overall survival (OS) from surgery to the date of death. Patients still living were censored at the date of the last follow-up. Patients were grouped into tertiles of expression for survival analysis stratified according to mRNA expression and RPPA data. Median follow-up was calculated using inverted Kaplan-Meier plots. All tests were with type I error probability of 5%.
Experimental protocol and ethics
All experiments protocols were approved by the respective institute performing the analysis. The clinical research ethics board of each institution approved this study and all patients consented to analysis of their tumor tissues (Bern, Switzerland KEK-Be 219/2015; Vancouver, Canada H09-01628; Southampton, UK, 10/H0405/99).
We assembled a cohort of 127 patients with MIBC from three centers. Clinical and pathologic characteristics as well as the number of samples subjected to each mode of analysis (FISH, mRNA expression, IHC) are provided in Supp Table 1. Tissue was derived from the pre-treatment TURBT, and all patients subsequently received NAC.
Association between ERBB2 gene amplification and expression
In the NAC cohort, FISH revealed that 16/83 tumors harbored ERBB2 amplification, while 24/127 had high Her2 protein expression by IHC (i.e. IHC score = 3). Samples with ERBB2 amplification had higher mRNA (p < 0.001) and protein expression (p < 0.001) (Fig. 2A and C), and mRNA and protein expression were significantly related to each other (p < 0.001) (Supp Figure 2A). However, not all amplified samples had high mRNA and protein expression. Six of 16 amplified samples had mRNA expression in the 1st tertile, and 10/16 had IHC scores of either 1 (n = 5) or 2 (n = 5). Furthermore, 19/67 non-amplified samples had a high mRNA expression (in the 3rd tertile) and 13/83 had an IHC Score 3, suggesting that gene amplification is not the sole driver of high Her2 expression in bladder cancer.
Findings in the TCGA bladder cohort were similar. mRNA and protein expression were significantly higher in amplified samples (p < 0.001, Fig. 2B and D) and correlation between mRNA and protein expression was strong (r: 0.72, p < 0.001, Supp Figure 2B). Not surprisingly, amplified cases had the lowest rate of ERBB2 methylation (p < 0.001, Supp Figure 2C). However, once again a significant proportion of patient tumors (115/403 and 99/339 respectively) without ERBB2 amplification had high (in the 3rd tertile) mRNA and protein expression, and some patients with amplification did not have expression. This may be due to epigenetic factors, since the ERBB2 amplified cases with the lowest mRNA expression had the highest rate of ERBB2 methylation (r: −0.62, p < 0.001, Supp Figure 2D).
SNVs in ERBB2 and relationship to amplification and expression
In the TCGA cohort, 45/407 (11%) tumours harbored missense SNVs in ERBB2 (Fig. 3A). Almost half of the mutations (20/45) fell in the Furin-like domain at position 310aa, a well-known mutational hotspot in ERBB2. Interestingly, 4 samples harboured both an SNV and concomitant amplification of ERBB2 (Fig. 3B). Three of these four samples had a mutant allele frequency of >85% which implies that the SNV was present in all alleles and therefore occurred before the amplification of ERBB2. mRNA and protein expression was not significantly different between samples with or without ERBB2 mutations and the expression in samples with ERBB2 mutation appeared to be primarily dependent on copy number variance rather than the location of the mutation (Fig. 3C). Interestingly however, SNVs in the extracellular domain resulted in lower detected protein expression by RPPA compared to SNVs in the intracellular domain (Fig. 3D).
In our own dataset (the NAC cohort), 15/83 (18%) samples had a missense SNV in ERBB2 and 6/15 were in the Furin-like domain. The trend towards lower protein expression/detection in cases with mutation in the extracellular domain was not significant. Importantly, ERBB2 copy number from FISH experiments were significantly related to the copy number estimation (log2[ratio]) from exome sequencing, providing robust inter-platform validation (p = 0.03, Supp Figure 2E–G).
We identified four tumors (across both cohorts) with ERBB2 amplification on the background of a relatively ‘quiet’ overall genome copy number profile (one in our NAC: Fig. 3E, upper panel; three in TCGA: Supp Figure 3). Interestingly, three of these ‘exclusively’ ERBB2 amplified tumors had both high Her2 mRNA and protein expression, and were classified in cluster I. The sample with low mRNA and protein expression was classified in cluster III. None of these 4 samples had an ERBB2 SNV. All other samples with ERBB2 amplification also harbored CNV in other well-known oncogenes (e.g. CCND1, CCNE1) (Fig. 3E, lower panel).
Her2 in relation to TCGA clusters
In general, Her2 alterations were higher in the luminal TCGA clusters (cluster I and II) compared to the basal clusters (cluster III and IV). In the TCGA cohort, the amplification rate and protein expression were highest in cluster I mRNA expression in cluster I and II was comparable but significantly higher than in cluster III and IV (Fig. 4). Our findings in the NAC cohort were virtually identical (Supp Figure 4). ERBB2 amplification, mRNA and protein expression were highest in cluster I. The amplification rate, mRNA and protein expression were lower in cluster II but still higher than in clusters III and IV.
Her2 and relation to clinical outcomes
None of the Her2 alterations, including SNVs, were related to pathologic response to NAC when response was defined as no residual muscle invasive disease (<ypT2N0). This was true when considering the entire cohort, and when considering the subtypes separately.
In the entire NAC cohort, Her2 alterations including SNVs were not related to overall survival (Supp Figure 5A,C and E). Similar to findings in the NAC cohort Her2 alterations failed to stratify survival in the entire TCGA bladder cohort (Supp Figure 5B,D and F).
Novel targeted therapies have revolutionized the treatment of many cancers. One of the best examples of this has been targeting of Her2 in overexpressing breast and gastric cancers7,29,30. However, no similar breakthroughs have been achieved in MIBC and inhibition of Her2 has demonstrated scant antitumor activity in clinical trials17,18,19. Targeting Her2 only in MIBC patients with Her2-overexpression and/or ERBB2 amplification was similarly unsuccessful17,18,19,20. The reason for this discrepancy between positive Her2 status and lack of antitumor activity is to date unclear. In this study we report that a comprehensive analysis of Her2 alterations at the DNA, RNA and protein levels reveals a complex landscape where only selected tumors have bona fide evidence of Her2 driver status. Prior clinical trials investigating Her2-targeted therapies in MIBC have been limited by their use of only FISH and IHC for patient selection17,18,19, and by the absence of Her2 cut-off levels validated specifically for bladder cancer. We posit that our findings may help to enrich future clinical trials investigating Her2-targeted therapies in MIBC with patients most likely to respond.
In general, an increase in ERBB2 copy number resulted in higher mRNA and protein expression in our own and the TCGA cohort. However, ERBB2 amplification was detected without overexpression of Her2 in some cases, while overexpression of Her2 was observed without ERBB2 amplification in others. This suggests that Her2 overexpression is regulated by mechanisms other than gene amplification. Indeed, tumors with ERBB2 amplification but low expression tended to have increased gene methylation, implying an important role for epigenetic control. Even among cases with concomitant overexpression, ERBB2 amplification may be a bystander event in most MIBC. MIBC is characterized by a high rate of genomic alterations14, reducing the probability that any individual alteration is a significant and non-redundant oncogenic driver. In rare cases, a combination of ERBB2 amplification with high mRNA and/or protein expression and the absence of other major genomic alterations might be necessary to implicate Her2 as a driver in an individual tumor. In line with data from colorectal cancer31, this hypothesis could be verified with patient-derived primary xenografts using Her2 targeted agents. However, this hypothesis will ultimately need testing in clinical trials.
Our findings may suggest that SNVs in the extracellular domain of ERBB2 seem to result in a detection of lower protein expression compared to SNVs in the intracellular domain. This apparent reduced expression may in fact reflect lower affinity of the antibody to the mutated extracellular domain rather than a true alteration of protein expression. Likely, due to the smaller sample size we were not able to validate this finding in our NAC cohort. This finding also might have implications for clinical trials that select patients based on Her2 expression by IHC, where expression may appear artificially low. Furthermore, monoclonal antibodies such as trastuzumab and TDM-1 that target the extracellular domain of Her2 may be rendered ineffective by their inability to bind to the target. Interestingly, somatic mutations in the intracellular tyrosine kinase domain are reported to modulate Her2 signaling, resulting in increased Her2 activation and even resistance to lapatinib in bladder and breast cancer32,33. In addition, somatic ERBB2 SNVs have been discussed in the context of resistance to trastuzumab34. However, none such data exist from bladder cancer. Remarkably, different DNA alterations can occur sequentially, few cases showed SNVs and coincident amplification of ERBB2 with different chronology, a phenomenon that was also noted in a separate cohort with metastasising MIBC35. Taken together, beside amplification of the ERBB2-gene, it is likely that further somatic DNA alterations influence success when targeting Her2.
Our results suggest that alterations in ERBB2, that are not detectable by ERBB2/HER2 FISH or IHC alone, might have contributed to previously unsuccessful clinical trials of Her2-targeted therapies in MIBC patients. Algorithms for appropriate patient selection for Her2-targeted therapies are well-established and in routine clinical use in breast cancer26. However, their direct transfer to MIBC appears to be confounded by the different spectrum of Her2 alterations and the specific context in which they occur (e.g. subtypes, highly mutated and/or unstable genomes). Based upon our study, we propose a potential system for prioritizing patients with MIBC for different Her2-targeted therapies based on specific combinations of Her2 alterations (Fig. 5) that could be explored in clinical trials. In brief, patients with ERBB2 gene amplification but no overexpression of Her2 are likely best treated with alternative therapies. Patients with ERBB2 amplification and Her2 overexpression in association with other major genomic alterations but in the absence of SNVs in the extracellular domain may benefit from TDM-1, the antibody drug-conjugate that requires Her2 overexpression for delivery of the cytotoxic payload, but is independent of Her2 pathway activity36. Finally, patients with ERBB2 gene amplification and protein overexpression in the absence of ERBB2 SNVs and other major genomic alterations may benefit most from trastuzumab or lapatinib (or other Her2-targeting tyrosine kinase inhibitors). As described above, mutations in either the extracellular or intracellular domain may have implications for trastuzumab or tyrosine kinase inhibitors, respectively. We are aware that this blueprint must be clinically qualified, and remains speculative in the meantime.
Recently elucidated molecular subtypes of MIBC based on gene expression are providing a framework for dissecting bladder cancer biology 14,21,22,23. Our results reinforce the need to consider potential biomarkers in the context of molecular subtypes. We observed that ERBB2 amplification, mRNA expression and protein expression were all significantly higher in tumors with luminal characteristics (cluster I and II). It is entirely plausible that genuine biological differences between basal and luminal MIBC influenced the results of recent clinical trials20. For example, lapatinib was considered particularly desirable via its dual inhibition of Her1 and Her2. On this basis, Her1 and/or Her2 positive patients were selected by IHC for enrollment in this trial20. Even excluding the likelihood that Her1 and Her2 overexpressing MIBC are biologically distinct entities21,22,23, the overall survival differences between patients with basal (enriched with Her1 positive) and luminal (enriched with Her2 positive) MIBC would probably confound trial outcome interpretation. Underscoring this hypothesis is our result showing that despite their established and potent oncogenic effect, Her2 alterations were not associated with poor overall survival.
Our study is not without limitations that are mainly due to its retrospective character. The focus of this manuscript was not to investigate the prognostic impact of Her2 in MIBC but to elucidate the intricacies of Her2 alterations at the DNA, RNA and protein levels, and highlight the significance of molecular subtypes in this context. The amplification rate of 19% in our NAC cohort is high compared to previous data including to our own experience of ERBB2 amplification in MIBC37. However, we were able validate our FISH data by genomic DNA sequencing. In addition, the threshold for ERBB2 amplification determined by FISH has been modified26. According to the historical threshold, the amplification rate in our NAC cohort would be 12%, which is consistent with previous findings in MIBC.
Our study of ERBB2/Her2 is exemplary for the type of analysis that may be necessary also for other targets in MIBC. FGFR3 alterations, for example vary according to protein expression, mutation, gene fusion and copy number, and it is not clear which is most relevant for success of FGFR3-targeted therapy. This is in apparent contrast to the success of targeted therapy in breast and gastric cancer where exclusive evaluation of Her2 protein expression via IHC (at least in patients with score 3) is sufficient to prioritize patients for Her2 targeted therapy. It is plausibly explained in these cancers by high concordance between gene status determined by FISH and protein expression (87.5% in gastric cancer38 and breast cancer 87.3%39). Contrarily, this concordance is lower in MIBC, which also has a higher rate of alterations across the entire genome. This latter characteristic may make FISH or IHC alone insufficient for selection of MIBC patients for Her2 targeted therapy.
Assessment of Her2 alterations at the DNA, RNA and protein level provides a much more comprehensive insight into Her2 relevance as a driver gene and a therapeutic target in MIBC, than through FISH or IHC alone. The complex molecular landscape of Her2 alteration has probably confounded previous clinical trials of Her2-targeted therapies, and improved patient selection accounting for multi-modal Her2 status and tumor molecular subtype will be essential for future clinical trial design.
How to cite this article: Kiss, B. et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci. Rep. 7, 42713; doi: 10.1038/srep42713 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Madersbacher, S. et al. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21, 690–696 (2003).
Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 19, 666–675 (2001).
Bajorin, D. F. & Herr, H. W. Kuhn’s paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 2135–2137, doi: 10.1200/JCO.2010.34.0471 (2011).
Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine 349, 859–866, doi: 10.1056/NEJMoa022148 (2003).
Zehnder, P. et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU international 112, E51–58, doi: 10.1111/bju.12215 (2013).
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920, doi: 10.1016/S0140-6736(16)00561-4 (2016).
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697, doi: 10.1016/S0140-6736(10)61121-X (2010).
Bear, H. D. et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England journal of medicine 366, 310–320, doi: 10.1056/NEJMoa1111097 (2012).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine 364, 1995–2005, doi: 10.1056/NEJMoa1014618 (2011).
Gomez-Martin, C. et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 4445–4452, doi: 10.1200/JCO.2013.48.9070 (2013).
Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 5287–5312, doi: 10.1200/JCO.2007.14.2364 (2007).
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. The New England journal of medicine 360, 563–572, doi: 10.1056/NEJMoa0808268 (2009).
Begnami, M. D. et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 3030–3036, doi: 10.1200/JCO.2010.33.6313 (2011).
Cancer Genome Atlas Research, N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322, doi: 10.1038/nature12965 (2014).
Kruger, S. et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. International journal of cancer 102, 514–518, doi: 10.1002/ijc.10731 (2002).
Ohta, J. I. et al. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 7, 2463–2467 (2001).
Hussain, M. H. et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 2218–2224, doi: 10.1200/JCO.2006.08.0994 (2007).
Oudard, S. et al. Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European journal of cancer 51, 45–54, doi: 10.1016/j.ejca.2014.10.009 (2015).
Wulfing, C. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881–2890, doi: 10.1002/cncr.24337 (2009).
Powles, T., Huddart R. A. & Elliot T. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo after First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor1/2 Positive Metastaic Bladder Cancer. Journal of Clinical Oncology, doi: 10.1200/JCO.2015.66.3468 (2016).
Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer cell 25, 152–165, doi: 10.1016/j.ccr.2014.01.009 (2014).
Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America 111, 3110–3115, doi: 10.1073/pnas.1318376111 (2014).
Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 3377–3386, doi: 10.1158/1078-0432.CCR-12-0077-T (2012).
LH, S. TNM Atlas: 7th ed.New York:Wiley-Lyss Inc. TNM Atlas2009. TNM Atlas: 7th ed. New York:Wiley-Lyss Inc. TNM Atlas 2009. (2009).
Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine 4, 844–847 (1998).
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 3997–4013, doi: 10.1200/JCO.2013.50.9984 (2013).
Lockstone, H. E. Exon array data analysis using Affymetrix power tools and R statistical software. Briefings in bioinformatics 12, 634–644, doi: 10.1093/bib/bbq086 (2011).
Piccolo, S. R. et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100, 337–344, doi: 10.1016/j.ygeno.2012.08.003 (2012).
Barok, M., Tanner, M., Koninki, K. & Isola, J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer letters 306, 171–179, doi: 10.1016/j.canlet.2011.03.002 (2011).
Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer research 68, 9280–9290, doi: 10.1158/0008-5472.CAN-08-1776 (2008).
Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer discovery 1, 508–523, doi: 10.1158/2159-8290.CD-11-0109 (2011).
Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer discovery 3, 224–237, doi: 10.1158/2159-8290.CD-12-0349 (2013).
Kancha, R. K. et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PloS one 6, e26760, doi: 10.1371/journal.pone.0026760 (2011).
Sun, Z. et al. Analysis of different HER-2 mutations in breast cancer progression and drug resistance. Journal of cellular and molecular medicine 19, 2691–2701, doi: 10.1111/jcmm.12662 (2015).
Tschui, J. et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Archiv: an international journal of pathology 466, 703–710, doi: 10.1007/s00428-015-1729-4 (2015).
Hayashi, T. et al. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. The Journal of urology 194, 1120–1131, doi: 10.1016/j.juro.2015.05.087 (2015).
Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E. & Thalmann, G. N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. European urology 60, 350–357, doi: 10.1016/j.eururo.2011.05.035 (2011).
Ruschoff, J. et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Archiv: an international journal of pathology 457, 299–307, doi: 10.1007/s00428-010-0952-2 (2010).
Sarode, V. R. et al. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate. Archives of pathology & laboratory medicine 139, 922–928, doi: 10.5858/arpa.2014-0127-OA (2015).
Grant support: RS – Salary funded by the Swiss National Foundation (P3SMP3_151738/1). This study was supported by Grant 36–418 (RS) from the Bern Cancer League.
Employment: Two authors (C.B., E.D.) are employees of GenomeDx Biosciences, which funded the gene expression analysis of the patient from the NAC cohort and assisted in the bioinformatics data analysis. The remaining authors have no direct or indirect commercial financial incentive associated with publishing the article.
About this article
Cite this article
Kiss, B., Wyatt, A., Douglas, J. et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep 7, 42713 (2017). https://doi.org/10.1038/srep42713
Scientific Reports (2022)
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
Nature Communications (2021)
A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer
Scientific Reports (2021)
Der Urologe (2021)
Nature Reviews Clinical Oncology (2020)